ArticleCommunications medicine2026

Neoadjuvant transarterial chemoembolization with tyrosine kinase and immune checkpoint inhibitors improves survival from resectable hepatocellular carcinoma in a multicenter, retrospective study (GUIDANCE002).

Da-Long Yang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.